Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tango rewire the brain? dance program tested for Parkinson's and dementia

NCT ID NCT07824128

Symptom relief Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers at Emory University are studying a modified Argentine tango program called Adaptango for adults with Parkinson's disease, mild cognitive impairment, or dementia, alongside younger adults. Over three months, participants take part in biweekly choreographic sessions that end with a performance workshop. The study measures creativity, satisfaction, and quality of life to see how dance affects thinking, movement, and community building.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Adaptango Performance Process, a modified Argentine tango dance program
What this could lead to
If the program helps, it could offer a low-risk, community-based way to support movement, thinking, and social connection for people with neurodegenerative conditions.
What could go wrong
This is a small, early study without a comparison group, so any improvements may be due to social contact or expectation rather than the dance itself. Participants must be able to attend sessions and have mild to moderate cognitive impairment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals (PWP, younger adults, PLwD) from the greater Atlanta area. Those in the PWP group must be diagnosed by a neurologist specialized in Parkinson's disease. * Score of at least 18 on the Montreal Cognitive Assessment (MoCA). Those who are in the PLwD group must score between 18 and 25 on the MoCA. Exclusion Criteria: * Acute medical illness requiring hospitalization * Uncontrolled congestive heart failure * History of stroke in the past three years * Inability to perform study procedures * Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity) * Taking medications that could adversely affect cognition, e.g., antipsychotics, opioids, stimulants, chemotherapy, neurologic prescriptions to treat Multiple sclerosis. When applicable, enrollment will be delayed until dosages are stable on, e.g., Aricept, Namenda, anticholinesterase inhibitors, for at least 3 months * Psychotic disorders * Confounding neurologic conditions \[e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness \>30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae\] * Substance Use Disorder, Major Depressive Disorder, and Generalized Anxiety Disorders within six months of evaluation * Unable to provide informed consent * Cognitively impaired individuals or individuals with impaired decision-making, individuals who are not yet adults, pregnant women, prisoners * Not able to clearly understand English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment Old age; dementia Parkinson disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory University, Executive Park, Wesley Woods

    Atlanta, Georgia, 30329, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.